DWA
ADAP

Dorsey Wright & Associates’s Adaptimmune Therapeutics ADAP Stock Holding History

Dorsey Wright & Associates’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-425,833
Closed -$3.4M – 304
2020
Q3 		$3.4M Buy
+425,833
New +$3.73M 0.61% 44
2018
Q4 		– Sell
-381,348
Closed -$5.17M – 266
2018
Q3 		$5.17M Sell
381,348
-203,265
-35% -$2.13M 0.94% 53
2018
Q2 		$6.98M Buy
+584,613
New +$7.29M 1.02% 41

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dorsey Wright & Associates's ADAP Position: Q4 2020 in Review

Dorsey Wright & Associates sold out of Adaptimmune Therapeutics (ADAP) in Q4 2020, closing a stake of 425,833 shares — an estimated $3.4M sold.

Dorsey Wright & Associates first reported a position in ADAP in Q2 2018 and held it in 3 quarters. The position peaked at $6.98M in Q2 2018. 87 funds tracked by Wall St. Rank hold ADAP as of Q4 2020.

  • Dorsey Wright & Associates reported no remaining Adaptimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 425,833 Adaptimmune Therapeutics shares in Q4 2020, an estimated $3.4M.
  • Dorsey Wright & Associates first reported a position in Adaptimmune Therapeutics in Q2 2018 and held it in 3 quarters.
  • Dorsey Wright & Associates's Adaptimmune Therapeutics position peaked at $6.98M in Q2 2018.
  • 87 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2020.

Based on Dorsey Wright & Associates's 13F filing for Q4 2020, filed 28 Jan 2021.